Ebert T, Kralisch S, Loessner U, Jessnitzer B, Stumvoll M, Fasshauer M, Tönjes A
Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany.
Horm Metab Res. 2014 Sep;46(10):685-90. doi: 10.1055/s-0034-1382078. Epub 2014 Jul 10.
Angiopoietin-related growth factor (AGF, also known as angiopoietin-like protein 6) has been introduced as a novel hepatocyte-derived factor, which antagonizes obesity and insulin resistance in mice. However, human studies show conflicting results and are limited to a small cohort of patients. In the current study, we therefore sought to investigate AGF serum levels in a large metabolically well-characterized cohort. AGF serum concentrations were determined by commercial enzyme-linked immunosorbent assay in 697 patients of a cohort from Eastern Germany (Sorbs). Correlations of AGF serum levels with clinical and biochemical measures of glucose and lipid metabolism, as well as markers of renal function, were investigated. In nondiabetic subjects (n=627), AGF was positively correlated with markers of insulin resistance and negatively correlated with high-density lipoprotein cholesterol in univariate analyses (p<0.05). After adjustment for age, gender, and body mass index, none of these factors remained independently associated with AGF, neither in nondiabetic subjects nor in patients with type 2 diabetes mellitus (T2DM) (n=70). However, we confirmed existing data of significantly higher AGF concentrations in patients with T2DM as compared to controls in this large cohort. Circulating AGF is elevated in subjects with T2DM and related to the type of antidiabetic treatment, but is not independently associated with anthropometric parameters, indices of insulin sensitivity and secretion, or a number of other adipokines.
血管生成素相关生长因子（AGF，也称为血管生成素样蛋白6）已被作为一种新型的肝细胞衍生因子引入，它可拮抗小鼠的肥胖和胰岛素抵抗。然而，人体研究结果相互矛盾，且仅限于一小部分患者。因此，在本研究中，我们试图在一个代谢特征良好的大型队列中调查AGF的血清水平。通过商业酶联免疫吸附测定法测定了来自德国东部（索布人）一个队列的697名患者的AGF血清浓度。研究了AGF血清水平与葡萄糖和脂质代谢的临床及生化指标以及肾功能指标之间的相关性。在非糖尿病受试者（n = 627）中，单因素分析显示AGF与胰岛素抵抗指标呈正相关，与高密度脂蛋白胆固醇呈负相关（p<0.05）。在对年龄、性别和体重指数进行调整后，无论是在非糖尿病受试者还是2型糖尿病（T2DM）患者（n = 70）中，这些因素均不再与AGF独立相关。然而，我们在这个大型队列中证实了现有数据，即T2DM患者的AGF浓度明显高于对照组。T2DM患者的循环AGF升高，且与抗糖尿病治疗类型有关，但与人体测量参数、胰岛素敏感性和分泌指标或其他一些脂肪因子无关。
